Business Description
Dongwha Pharm Co Ltd
ISIN : KR7000020008
Compare
Compare
Traded in other countries / regions
000020.Korea IPO Date
1976-03-24Description
Dongwha Pharm Co Ltd is engaged in manufacturing and selling pharmaceutical products in South Korea. It offers ethical products in the areas of alimentary system, antibiotic, cardiovascular/metabolic disease, NSAID/ respiratory system, muscle relaxant/musculoskeletal system, nervous system, and dermatological/urinary system among several other products.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.53 | |||||
| Equity-to-Asset | 0.64 | |||||
| Debt-to-Equity | 0.2 | |||||
| Debt-to-EBITDA | 2.56 | |||||
| Interest Coverage | 5.42 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 2.39 | |||||
| Beneish M-Score | -2.12 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9.8 | |||||
| 3-Year EBITDA Growth Rate | 4.5 | |||||
| 3-Year EPS without NRI Growth Rate | 1.1 | |||||
| 3-Year FCF Growth Rate | -49.7 | |||||
| 3-Year Book Growth Rate | 3.8 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 48.92 | |||||
| 9-Day RSI | 46.52 | |||||
| 14-Day RSI | 42.91 | |||||
| 6-1 Month Momentum % | -17.45 | |||||
| 12-1 Month Momentum % | -33.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2 | |||||
| Quick Ratio | 1.29 | |||||
| Cash Ratio | 0.37 | |||||
| Days Inventory | 113.7 | |||||
| Days Sales Outstanding | 57.78 | |||||
| Days Payable | 52.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.83 | |||||
| Dividend Payout Ratio | 0.59 | |||||
| Forward Dividend Yield % | 2.83 | |||||
| 5-Year Yield-on-Cost % | 4.5 | |||||
| 3-Year Average Share Buyback Ratio | -0.1 | |||||
| Shareholder Yield % | -21.94 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 48.07 | |||||
| Operating Margin % | 2.1 | |||||
| Net Margin % | 1.79 | |||||
| FCF Margin % | -18.18 | |||||
| ROE % | 2.04 | |||||
| ROA % | 1.39 | |||||
| ROIC % | 1.23 | |||||
| ROC (Joel Greenblatt) % | 4.65 | |||||
| ROCE % | 2.53 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 23 | |||||
| PE Ratio without NRI | 20.76 | |||||
| PEG Ratio | 1.45 | |||||
| PS Ratio | 0.41 | |||||
| PB Ratio | 0.47 | |||||
| Price-to-Tangible-Book | 0.6 | |||||
| EV-to-EBIT | 21.07 | |||||
| EV-to-EBITDA | 8.1 | |||||
| EV-to-Revenue | 0.56 | |||||
| EV-to-FCF | -2.72 | |||||
| Price-to-Projected-FCF | 0.63 | |||||
| Price-to-DCF (Earnings Based) | 0.6 | |||||
| Price-to-Median-PS-Value | 0.42 | |||||
| Price-to-Peter-Lynch-Fair-Value | 3.37 | |||||
| Price-to-Graham-Number | 0.75 | |||||
| Price-to-Net-Current-Asset-Value | 25.76 | |||||
| Earnings Yield (Greenblatt) % | 4.75 | |||||
| FCF Yield % | -44.11 | |||||
| Forward Rate of Return (Yacktman) % | 5.28 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Dongwha Pharm Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 428,482.232 | ||
| EPS (TTM) (â‚©) | 277 | ||
| Beta | 0.76 | ||
| Volatility % | 19.14 | ||
| 14-Day RSI | 42.91 | ||
| 14-Day ATR (â‚©) | 166.993726 | ||
| 20-Day SMA (â‚©) | 6375 | ||
| 12-1 Month Momentum % | -33.03 | ||
| 52-Week Range (â‚©) | 5950 - 10760 | ||
| Shares Outstanding (Mil) | 27.72 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Dongwha Pharm Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Dongwha Pharm Co Ltd Stock Events
| Event | Date | Price(â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
Dongwha Pharm Co Ltd Frequently Asked Questions
What is Dongwha Pharm Co Ltd(XKRX:000020)'s stock price today?
The current price of XKRX:000020 is â‚©6370.00. The 52 week high of XKRX:000020 is â‚©10760.00 and 52 week low is â‚©5950.00.
When is next earnings date of Dongwha Pharm Co Ltd(XKRX:000020)?
The next earnings date of Dongwha Pharm Co Ltd(XKRX:000020) is .
Does Dongwha Pharm Co Ltd(XKRX:000020) pay dividends? If so, how much?
The Dividend Yield %  of Dongwha Pharm Co Ltd(XKRX:000020) is 2.83% (As of Today), Highest Dividend Payout Ratio of Dongwha Pharm Co Ltd(XKRX:000020) was 0.59. The lowest was 0.12. And the median was 0.32. The  Forward Dividend Yield % of Dongwha Pharm Co Ltd(XKRX:000020) is 2.83%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers